Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDG3AD)

Drug Name

BIIB131 Drug Info

Synonyms

Orniplabin; SMTP-7; SMTP7; SMTP 7; SMTP7; BIIB131; SCHEMBL2624852; GTPL12300; TMS-007; BCP33210; Stachybotrys microspora triprenyl phenol 7; HY-122311; CS-0083560; (2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0

Indication

Disease Entry	ICD 11	Status	REF
Acute ischemic stroke	8B11	Phase 2	[1]

Cross-matching ID

PubChem CID: 50898407
TTD Drug ID: DMDG3AD

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Plasminogen (PLG)	DTT	PLG	11.754	0.848	8.393	2.138

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute ischemic stroke

ICD Disease Classification

8B11

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Plasminogen (PLG)	DTT	PLG	8.61E-01	-0.01	-0.09

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Biogen